Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PRI-400
- Development stage
- Unknown
- Lead developer
- Priavoid
- Modality
- Peptides
01
Overview
PRI-400 is an experimental drug candidate being developed by Priavoid, currently in the discovery stage. It belongs to a proprietary class of "All-D-Peptides," which are synthetic peptides composed entirely of D-enantiomeric amino acids. This structural configuration is intended to enhance metabolic stability and reduce immunogenicity, as D-peptides are resistant to proteolytic degradation by endogenous enzymes. While Priavoid's broader pipeline focuses on neurodegenerative diseases by targeting protein misfolding and aggregation (such as amyloid-beta, alpha-synuclein, and tau), the specific biological target and therapeutic indication for PRI-400 have not yet been disclosed.
Beyond the preview
Go deeper on PRI-400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PRI-400.